Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Stallergenes Greer clinical trials
Part of Ares Life Sciences I S.à r.l..
The registry lists 28 studies whose lead sponsor is Stallergenes Greer or one of 1 company grouped under it. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 26, 2025.
Registry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Stallergenes Greer.
- Stallergenes Greer26 studiesSame company
Something wrong?
- Greer Laboratories2 studies →Acquired — became part of Stallergenes Greer, Sep 8, 2015 · source ↗
Something wrong?
Focus areas
Conditions Stallergenes Greer leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 28 of 28.
- Safety and Efficacy of STALORAL® Birch 300 IR in a Paediatric Population With Birch Pollen-induced ARC w/o AsthmaCompletedNCT05668390Phase 3
- Safety and Efficacy Study of Sublingual Immunotherapy (SLIT) to Treat House Dust Mite Allergic Rhinitis in Adolescents and ChildrenTerminatedNCT01199133Phase 3
- Efficacy and Safety of 100IR, 300IR, 500IR Sublingual House Dust Mite Tablets in Allergic Rhinitis Environment Exposure Chamber ModelCompletedNCT01527188Phase 2
- Safety Study of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts in AdolescentsCompletedNCT01919554Phase 1
- Evaluation of the Benefits of Sublingual AIT (PRACTIS)CompletedNCT06574061
- Efficacy & Safety of STG320 Sublingual Tablets of HDM Allergen Extracts in Adults and Adolescents With HDM-associated ARCompletedNCT02443805Phase 3
- Treatment Modalities in Children and Adolescents Suffering From HDM-induced Allergic Rhinitis and/or AsthmaCompletedNCT04004351
- Observational Study of Oralair® in Children 5-9 Years With Grass-pollen-induced Allergic Rhinitis With/Without ConjunctivitisCompletedNCT02295969
- Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Children Suffering From Grass Pollen RhinoconjunctivitisCompletedNCT00409409Phase 3
- Safety and Efficacy on Phase III Study on 300 IR SLIT to Patients Suffering From Grass Pollen RhinoconjunctivitisCompletedNCT00803244Phase 3
- Phase III Study to Assess the Long Term Efficacy, Carry-over Effect and Safety of 300 IR Sublingual Immunotherapy TabletsCompletedNCT00418379Phase 3
- Safety and Efficacy of Sublingual Immunotherapy (SLIT) Tablets in Grass Pollen RhinoconjunctivitisCompletedNCT00367640Phase 2/3
- Efficacy and Safety of Sublingual Tablets of Grass Pollen Allergen ExtractCompletedNCT00619827Phase 1
- Study of Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Adult Patients With Allergic Grass Pollen RhinoconjunctivitisCompletedNCT00955825Phase 3
- Safety and Efficacy Study of Sublingual Immunotherapy (SLIT) to Treat House Dust Mite Allergic RhinitisCompletedNCT00674700Phase 2/3
- International Registry on the Quality of Life of Patients With Grass-pollen-induced Allergic RhinitisTerminatedNCT02041624
- Dose Ranging Study of SLIT Tablets of House Dust Mite Allergen Extracts (HDM) in Adults With HDM-associated Allergic AsthmaCompletedNCT01930461Phase 2
- Efficacy and Safety Study Of Short Ragweed Pollen Sublingual-Oral ImmunotherapyCompletedNCT01353079Phase 3
Sponsor listed in the registry: Greer Laboratories · First submitted before Greer Laboratories became part of Stallergenes Greer
- Efficacy Study of Sublingual Immunotherapy to Treat Ragweed AllergiesCompletedNCT00599872Phase 3
Sponsor listed in the registry: Greer Laboratories · First submitted before Greer Laboratories became part of Stallergenes Greer
- Safety Study of Sublingual Immunotherapy Tablets of House Dust Mite Allergen ExtractsCompletedNCT01608243Phase 1
- Sensitivity and Specificity of 3 Solutions of Allergen Extract for Diagnosis by Skin Prick TestingCompletedNCT01964768Phase 3
- Safety, Tolerability and Pharmacodynamic Effects of Sublingual Immunotherapy (Tablets) With Recombinant Bet v1CompletedNCT00396149Phase 1
- Study of rBet v1 TabletsCompletedNCT00901914Phase 2
- Efficacy and Safety Study of a Sublingual Immunotherapy Solution to Treat Patients Suffering From Birch Pollen Allergic RhinoconjunctivitisCompletedNCT01731249Phase 3
- A Phase III Study to Assess Efficacy and Safety of STALORAL® 300 IR Sublingual Immunotherapy (SLIT) in Asthmatic Patients Allergic to House-dust MitesCompletedNCT00660452Phase 3
- Safety and Tolerability Study of Ragweed SLIT TabletsCompletedNCT01224834Phase 1
- Safety and Tolerability Study of rBet v1 SLIT TabletsCompletedNCT00889460Phase 1
- Efficacy and Safety of Subcutaneous Immunotherapy in Birch Pollen Allergic PatientsTerminatedNCT00410930Phase 2